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Cell-based therapeutic strategies for multiple
sclerosis
Neil J. Scolding,1 Marcelo Pasquini,2 Stephen C. Reingold3 and Jeffrey A. Cohen4 on behalf of
attendees at the International Conference on Cell-Based Therapies for Multiple Sclerosis
The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substan-
tial progress made in therapy of the disease. However, all are only partially effective in preventing inﬂammatory tissue damage in the
central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologous
haematopoietic stem cell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of en-
dogenous stem cells to enhance their reparative capabilities, and transplantation of oligodendrocyte progenitor cells, have generated
substantial interest as novel therapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervous
system in multiple sclerosis. Each approach has potential advantages but also safety concerns and unresolved questions. Moreover,
clinical trials of cell-based therapies present several unique methodological and ethical issues. We summarize here the status of cell-
based therapies to treat multiple sclerosis and make consensus recommendations for future research and clinical trials.
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Introduction
With multiple approved disease-modifying therapies
(DMTs), there is a broad range of options to treat relap-
sing-remitting multiple sclerosis (Ingwerson et al., 2016).
However, less progress has been made in the treatment of
progressive forms of the disease (Shirani et al., 2016).
While the positive impact of treatment on reducing the fre-
quency of relapses and accrual of relapse-related disability
has been demonstrated, none of the currently available
agents halt disease progression or directly promote repair
of pre-existing CNS damage. Moreover, all of the approved
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therapies have potential adverse events that may comprom-
ise safety or adherence. All are expected to be ongoing
life-long therapies as long as they remain safe and effective.
Consequently, there is an imperative for new therapies that
(i) are more effective in relapsing-remitting multiple scler-
osis, particularly for patients with highly active disease who
are at substantial risk for future disability; (ii) are effective
in slowing or preventing progression; (iii) have the potential
to reverse disability; and (iv) can be used safely with fewer
delivery and adherence concerns.
Cell-based therapies have generated substantial interest as
potential approaches to address these gaps by working
through various mechanisms: regenerating the defective
immune system that underlies multiple sclerosis by immu-
noablation followed by autologous haematopoietic stem
cell transplantation (I/AHSCT); modifying both immune re-
actions and endogenous repair mechanisms using mesenchy-
mal stem cells (MSCs) and other stem cells from bone
marrow, adipose tissue, placenta, or other tissues; pharma-
cologic manipulation of endogenous stem cells to enhance
their reparative capabilities; or replacing damaged or lost
myelin-making oligodendrocytes by transplantation of oligo-
dendrocyte progenitor cells (OPCs) or OPC-like inducible
pluripotent stem cells (iPSCs) (Sarkar and Scolding, 2016).
In this review, we discuss the biology and potential utility of
these cell-based therapeutic approaches in multiple sclerosis;
summarize the progress made to date on testing in multiple
sclerosis; discuss practical, scientiﬁc, clinical, regulatory, and
ethical concerns; and make recommendations for future studies
to move this therapeutic area forward. The review is based on
an extensive literature search related to cell-based therapies for
multiple sclerosis and on discussions at a consensus workshop,
the International Conference on Cell-Based Therapies for mul-
tiple sclerosis, held 19–21 November 2015 in Lisbon Portugal
under the auspices of the International Advisory Committee
for Clinical Trials in Multiple Sclerosis (see Appendix 1 and
Supplementary material for a list of conference participants).
Immunoablation followed by
haematopoietic stem cell
transplantation
Biological background and rationale
The rationale for I/AHSCT to treat multiple sclerosis is
depletion of autoreactive effector cells with immunoablative
agents (the conditioning regimen) followed by infusion of
autologous haematopoietic stem cells to support immune
system reconstitution with more normal immune function
(Muraro et al., 2005; Muraro and Abrahamsson, 2010).
Analysis of circulating lymphocytes after I/AHSCT demon-
strates reduction of circulating autoreactive effector T cells,
predominantly Th17 rather than Th1, and emergence of
recent thymic emigrants post-transplant, restoring a more
regulatory milieu (Muraro et al., 2005, 2014; Darlington
et al., 2013; Arruda et al., 2015). The degree of reconsti-
tuted T cell repertoire variability is related to the intensity
of the conditioning regimen (Muraro et al., 2014). Muraro
et al. (2014) reported the presence, pre-transplant, of cir-
culating mucosal-associated invariant T cells (MAITs) char-
acterized by a CD8+ , CD161high phenotype (Abrahamsson
et al., 2013). These MAITs exert a pro-inﬂammatory effect
by promoting production of several cytokines thought to be
associated with the pathogenesis of multiple sclerosis,
including interferon-gamma and interleukin-17 (Lovett-
Racke et al., 2011). After transplantation, there was a sig-
niﬁcant reduction of this population in the peripheral blood
in parallel with an increase of regulatory CD4+ , CD25high,
CD127-, FoxP3+ T cells. The initial beneﬁt of I/AHSCT
probably results from this and other comparable alterations
in immune function. However, some studies have detected
re-emergence of autoreactive effector cells despite a high
intensity conditioning regimen and persistence of efﬁcacy
(Darlington et al., 2013). Thus, the mechanisms responsible
for sustained beneﬁt of I/AHSCT are less well understood.
Practical/procedural background
Appropriate patients for I/AHSCT
Recognition of patients with multiple sclerosis most likely to
beneﬁt from I/AHSCT has evolved. Initial studies mainly en-
rolled patients with longstanding severe progressive multiple
sclerosis, when inﬂammatory features are less prominent and
neurodegeneration is the main underlying mechanism (Trapp
and Nave, 2008). Beneﬁt generally was modest, although
some patients exhibited sustained slowing or stabilization of
disability, but improvement in neurologic function was rarely
seen (Burt et al., 2015; Mancardi et al., 2015). Also, patients
with more severe neurologic disability had increased risk of
adverse events (Mancardi and Saccardi, 2008). More recent
studies (Table 1) focused on relapsing-remitting multiple
sclerosis and demonstrated that patients with active inﬂam-
matory features appear to derive the most beneﬁt from this
approach (Burt et al., 2012; Saccardi et al., 2012; Muraro
et al., 2017). As a result, the current recommendation is for
studies of I/AHSCT to enrol patients with highly active relap-
sing-remitting multiple sclerosis reﬂected by clinical relapses
and MRI lesion activity, time from diagnosis within 5 years,
and suboptimal response to available regulatory-approved
DMTs (Burt et al., 2012; Saccardi et al., 2012). These criteria
apply to only a limited subset of patients with multiple scler-
osis but help deﬁne those at high risk for future disability
despite available therapy. These recommendations have been
somewhat controversial, as they suggest a relatively aggres-
sive therapeutic approach for patients who may have little
established disability (Soelberg Sorensen, 2016).
An important determinant of transplant success is the
ability of patients to tolerate the conditioning regimen.
Disease-related factors not only affect efﬁcacy but also tol-
erability. In cancer patients, those with more advanced
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disease, either with active cancer at time of transplant or
refractory to prior therapy, have a higher failure rate. This
is not only due to inability to control the disease with
higher doses of chemotherapy, but also the increase in
transplant-related morbidity or mortality from the cumula-
tive effect of prior treatments. Similarly, multiple sclerosis
patients with more severe disability or progressive disease
also tend to have higher rates of transplant-related morbid-
ity and mortality (Mancardi and Saccardi, 2008; Muraro
et al., 2017). The effects of prior multiple sclerosis DMTs
on efﬁcacy or safety of I/AHSCT are unknown.
In allogeneic haematopoietic stem cell transplantation for
haematologic malignancies, the overall impact of the cancer
on general health (the estimated the ability to work, perform
activities of daily living and the need for hospitalization) is
correlated with transplant outcome; lower performance
scores are associated with higher post-transplant mortality.
Similarly, the presence of key comorbid conditions also im-
pacts transplant outcome. A high score on the
Haematopoietic Cell Transplantation Comorbidity Index,
which includes 17 items comprising past medical history
(stroke, myocardial infarction, arrhythmia, autoimmune dis-
ease, prior solid tumours), end organ function (pulmonary,
hepatic, renal and cardiac), and weight (obesity), is asso-
ciated with increased post-transplant mortality (Sorror
et al., 2005, 2015; Elsawy and Sorror, 2016). Although
comorbidities are less common in younger patients with
multiple sclerosis, they have an important impact on mul-
tiple sclerosis disease outcomes (Marrie et al., 2015). Their
effects on the efﬁcacy or safety of I/AHSCT to treat multiple
sclerosis have not been explored.
Transplant procedure
I/AHSCT should be viewed as a multi-step process that
leads to a combined therapeutic effect in multiple sclerosis.
Adverse effects also can occur at each step. The typical
sequence includes mobilization of peripheral blood haem-
atopoietic stem cells, immunoablation via administration of
a conditioning regimen, then infusion of haematopoietic
stem cells to promote haematologic reconstitution.
Granulocyte colony stimulating factor (G-CSF) or gran-
ulocyte-macrophage colony stimulating factor (GM-CSF)
are often used alone to mobilize haematopoietic stem cells
from the bone marrow to the peripheral blood in healthy
volunteer donors in an allogeneic donor transplant setting,
but may cause worsening of neurologic manifestations in
multiple sclerosis, either accentuation of pre-existing symp-
toms due to fever or bona ﬁde relapses (Openshaw et al.,
2000). Therefore, in multiple sclerosis, the most common
approach is administration of cyclophosphamide (Cy) plus
G-CSF as a mobilizing agent, which helps deplete lympho-
cytes that will eventually be collected in the graft and les-
sens the chance of reinfusion of autoreactive T cells.
Administration of Cy also may contribute to the thera-
peutic effect and adverse effects of I/AHSCT.
There are clear distinctions between the conditioning
regimens used to treat malignancies and for non-malignant
diseases such as multiple sclerosis. In the setting of AHSCT
for malignancies, the conditioning regimen consists of high
doses of chemotherapy to maximize disease control; the
primary intent of subsequent haematopoietic stem cell in-
fusion is to ‘rescue’ haematopoiesis. In the setting of allo-
geneic haematopoietic stem cell transplantation, the
conditioning regimen can be classiﬁed within an intensity
spectrum according to the type of chemotherapeutic agents
and/or radiation selected, and their respective doses. High
intensity regimens, also termed myeloablative, require
haematopoietic stem cell infusion to prevent irreversible
bone marrow damage. At the opposite end of the spectrum
are lower intensity regimens, also termed non-myeloabla-
tive, which minimally affect haematopoiesis. Intermediate
intensity regimens, also termed reduced intensity, fall in
the middle of this spectrum. The indication, type of trans-
plant, and population being treated determine the choice of
regimen intensity. For example, in some instances for the
same indication and transplant type, a high intensity regi-
men will be selected for patients younger than 65 years and
a reduced intensity in patients older than 65 years. In gen-
eral, high intensity regimens are selected to better control
the cancer and minimize the risk of disease relapse, but are
potentially associated with greater morbidity and mortality
compared to lower intensity regimens.
In multiple sclerosis, like other autoimmune diseases, the
optimal intensity of the conditioning regimen remains un-
certain and is actively debated. The main objective is to
balance lymphocyte depletion to eliminate pathologic auto-
immunity with acceptable morbidity and mortality. The
most commonly used conditioning regimen in multiple
sclerosis has been BEAM (carmustine, etoposide, cytarabine
and melphalan), which is considered an intermediate inten-
sity regimen, combined with anti-thymocyte globulin
(ATG) (Mancardi et al., 2012, 2015; Muraro et al.,
2013; Burman et al., 2014; Nash et al., 2015;
Shevchenko et al., 2015). High intensity regimens, such
as total body irradiation and busulfan, were initially used
in multiple sclerosis but were either abandoned or modiﬁed
because of toxicity. Atkins et al. (2016) reported the use of
high dose busulfan and Cy (Bu/Cy) with infusion of a T cell
depleted (CD34+ cell selection) autologous graft (Atkins
et al., 2016). During the study, several modiﬁcations to
the busulfan regimen were made to improve tolerability.
The route of administration was switched from oral to
intravenous, the dose was reduced (though still considered
in the high dose range), and the target dose was adjusted
based on the ﬁrst busulfan dose pharmacokinetics.
Conversely, Burt and colleagues (2009, 2015) have advo-
cated a low intensity or non-myeloablative regimen—Cy or
alemtuzumab followed by ATG—reporting good efﬁcacy in
relapsing-remitting multiple sclerosis with reduced toxicity
and no mortality.
One potential concern with use of a less intense condi-
tioning regimen is suboptimal multiple sclerosis disease
control. One study demonstrated that recipients of non-
myeloablative regimens had early reappearance of MRI
Stem cell therapy for multiple sclerosis BRAIN 2017: Page 3 of 21 | 3
lesion activity post-transplant (Mancardi et al., 2012). It is
possible that the intensity of the conditioning regimen may
need to be tailored to the clinical situation, although con-
sensus on how to identify patients early with aggressive
multiple sclerosis and poor prognosis is lacking. Another
consideration is whether the speciﬁc drug combination
within regimens considered the same intensity is associated
with differential outcomes. Muraro et al. (2017) analysed
data on 281 transplant recipients with multiple scler-
osis worldwide in a retrospect registry-based study.
Conditioning regimens varied greatly and when they were
grouped according to intensity, there was no correlation
with outcome. This observation may have been due to
most patients having progressive multiple sclerosis and
the proportion of patients with relapsing-remitting multiple
sclerosis was not sufﬁcient to demonstrate differential efﬁ-
cacy. Thus, the optimal regimen, Cy/ATG, BEAM-ATG, or
Bu/Cy remains uncertain and, based on the available data,
all remain acceptable options.
It remains uncertain whether haematopoietic stem cell
transplantation should be considered merely bone mar-
row rescue or if it contributes to the therapeutic beneﬁt
of I/AHSCT. While less intensive conditioning regimens
may not necessitate haematopoietic stem cell transplant-
ation, the infusion of haematopoietic stem cells serves
two purposes: (i) to reduce morbidity by shortening the
duration of pancytopenia; and (ii) to increase beneﬁt by
promoting immune reconstitution with broader clonal di-
versity without auto-reactivity. Characteristics of the graft
have received relatively little attention in multiple sclerosis.
Some studies have administered a largely unmanipulated
graft (Burman et al., 2014; Burt et al., 2015; Mancardi
et al., 2015). Other studies have positively selected
CD34+ cells ex vivo to remove any residual lymphocytes
in the graft (Nash et al., 2015; Atkins et al., 2016). This
step adds to the technical complexity of the transplant pro-
cedure but reduces the risk of reinfusion of potentially
autoreactive lymphocytes. If haematopoietic stem cell trans-
plantation is not merely rescue after immune depletion but,
in fact, contributes to the efﬁcacy of the procedure, further
work is needed to optimize mobilization and graft process-
ing to maximize potency.
Multiple sclerosis-related outcomes
Evaluation of therapeutic outcomes in multiple sclerosis is
complex. Assessment of the success of a therapeutic inter-
vention is more difﬁcult than in I/AHSCT for malignant
diseases, where transplant-related mortality, all-cause mor-
tality, and/or malignant disease recurrence often are used as
outcomes. Because multiple sclerosis is associated with only
modest shortening of life-span (Goodin et al., 2012), trans-
plant-related mortality or all-cause mortality alone are
not likely to be an informative efﬁcacy outcome in studies
of I/AHSCT in multiple sclerosis.
The outcomes most often used in multiple sclerosis clin-
ical trials are relapses, conﬁrmed worsening of disability
measured by the Expanded Disability Status Scale (EDSS)
or Multiple Sclerosis Functional Composite, MRI lesion
activity and burden, and normalized whole brain volume
(Cohen et al., 2012). As summarized in Table 1, these end-
points have been used in trials of I/AHSCT in multiple
sclerosis (Mancardi et al., 2012, 2015; Muraro et al.,
2013; Burman et al., 2014; Burt et al., 2015; Nash et al.,
2015; Shevchenko et al., 2015; Atkins et al., 2016).
Because of the potential risk associated with I/AHSCT
and to distinguish its efﬁcacy from that of available
highly effective multiple sclerosis therapies, some workshop
participants favoured a stringent outcome be utilized in
future trials of I/AHSCT in multiple sclerosis, speciﬁcally
event-free survival with a composite outcome comprising
clinical relapses, MRI lesion activity (new/enlarged T2-
hyperintense lesions or gadolinium-enhancing lesions), con-
ﬁrmed disability worsening, and normalized whole brain
volume. Whether the speciﬁc deﬁnitions of the outcome
components should be those used for so-called ‘no evidence
of disease activity’ (NEDA) in previous studies (Havrdova
et al., 2010; Giovannoni et al., 2015; Kappos et al., 2015;
Rotstein et al., 2015), or modiﬁed, e.g. to account for
delayed efﬁcacy in a highly active study population, was
not decided at the workshop. Other workshop participants
felt that early inhibition of inﬂammatory activity (clinical
relapses and MRI lesion activity) had uncertain relation to
long-term disease outcome (University of California San
Francisco MS-EPIC Team et al., 2016) and was not likely
to distinguish I/AHSCT from available highly effective
DMTs. They advocated focusing primarily on long-term
disability accrual. Thus, an important issue, especially
in relapsing-remitting multiple sclerosis, is how effectively
I/AHSCT alters the long-term disease course, that is, delays
or prevents development of progressive disease and disabil-
ity accrual, compared to available therapies. This determin-
ation will require a randomized trial comparing I/AHSCT
to DMTs with long-term follow-up. A related question is
whether I/AHSCT affects the subsequent response to, or
safety of, DMTs administered.
An additional efﬁcacy outcome potentially relevant for
clinical trials of I/AHSCT is conﬁrmed improvement in dis-
ability, which has been demonstrated in trials of several
multiple sclerosis DMTs (Jones et al., 2010; Phillips et al.,
2011; Hauser et al., 2015). Similarly, reversal of pre-existing
disability also has been reported with I/AHSCT (Burt et al.,
2015; Atkins et al., 2016). Although it is possible these inter-
ventions directly stimulate repair to some degree, it is more
likely they unmask intrinsic repair mechanisms by effectively
suppressing ongoing inﬂammatory damage (Chang et al.,
2002, 2008, 2012).
Financial cost
The annual costs of multiple sclerosis DMTs range from
$50000 to $70 000 (Hartung et al., 2015) in the USA.
The cost of I/AHSCT is $120 000 in the USA, which is
incurred mainly in the ﬁrst year with minimal direct costs
subsequently. Thus, in contrast to DMTs for which cost
accrues indeﬁnitely, the ﬁnancial cost of I/AHSCT is largely
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front-loaded and may be less expensive overall. However,
the procedure is not universally covered by health insur-
ance in the USA, although there is variation across different
centres and payors. Approaches in other transplant indica-
tions, e.g. myelodysplastic syndromes where Center for
Medicare Services established Coverage with Evidence
Development, allow coverage of transplant costs with the
requirement for systematic and prospective data collection.
Clinical trials to date
I/AHSCT has been the most investigated cell-based thera-
peutic strategy for multiple sclerosis. Recent clinical studies
are summarized in Table 1. Most studies were small or
single centre case series with different patient populations,
therapeutic protocols, and outcome measures. The pub-
lished experience mostly comprises uncontrolled studies.
The one randomized trial (Mancardi et al., 2015) used
mitoxantrone, an agent that is now largely less relevant
as a comparator.
A recent retrospective analysis indicated that treatment with
I/AHSCT achieved NEDA based on relapses, MRI lesion ac-
tivity, and disability worsening in a higher proportion of mul-
tiple sclerosis patients (78–83% at 2 years) than reported in
trials of the available DMTs (13–46%) (Sormani et al., 2017).
It should be noted that these studies had different patient
populations and visit schedules, particularly the frequency of
MRI scans, which can have a marked effect on NEDA rate. In
addition to potent beneﬁt on clinical measures and MRI lesion
activity, I/AHSCT had potent efﬁcacy on normalized whole
brain volume loss. Following I/AHSCT there was initial accel-
eration of, followed by marked slowing after 2 years to levels
approximating normal ageing (Roccatagliata et al., 2007; Lee
et al., 2017).
Any evaluation of the utility of I/AHSCT needs to assess risk
of mortality. In multiple sclerosis, mortality related to the dis-
ease may occur, but usually many decades after diagnosis.
Thus, any therapy with signiﬁcant risk of mortality will not
readily be accepted. Mortality associated with I/AHSCT has
decreased over the past two decades (Sormani et al., 2016).
With recent protocols, I/AHSCT is a safer procedure with mor-
tality rates 55% (Muraro et al., 2017), with some trials re-
porting no mortality (Burt et al., 2015). Risks remain
associated with the conditioning intensity, which necessitate
careful patient selection (excluding participants with signiﬁcant
recent or chronic infection, liver disease, heart disease, etc.) and
adequate supportive care during the 2–3-week aplastic phase.
Optimal selection of patients, transplant procedure, timing of
transplant, and post-transplant care help minimize the risk of
transplant-related mortality. Some delayed adverse events occur
late after I/AHSCT, but they are uncommon. The principal late
adverse event is a 9% risk of a secondary autoimmune dis-
order within 5 years of I/AHSCT to treat autoimmune disease
(Daikeler et al., 2011). Thus, the front-loading of safety issues
with I/AHSCT contrasts with multiple sclerosis DMTs, for
which the risk of ongoing therapy accumulates over time
related to chronic immune modulation or suppression.
Key questions/issues and
recommendations
Workshop participants generally agreed on several consen-
sus recommendations.
(i) In aggregate, the available evidence suggests I/AHSCT has
substantial and sustained efﬁcacy in suppressing inﬂamma-
tory disease activity in multiple sclerosis. However, at pre-
sent, it remains uncertain where the beneﬁt-risk-cost proﬁle
of I/AHSCT places it in the treatment for relapsing-remitting
multiple sclerosis relative to other available highly effective
DMTs.
(ii) Patients most likely to beneﬁt from I/AHSCT are relatively
young e.g. 50 years of age or less, with relatively short disease
duration e.g. 5 years or less, have active relapsing-remitting
multiple sclerosis and accumulating disability but still are
ambulatory, and have ongoing disease activity despite DMT.
I/AHSCT is unlikely to beneﬁt patients with longstanding pro-
gressive multiple sclerosis without recent inﬂammatory features
(clinical relapses or MRI lesion activity).
(iii) We recommend a formal, multicentre, randomized phase 3
trial, comparing I/AHSCT head-to-head versus currently
available highly effective therapy(ies) in a deﬁned patient
population. Issues concerning the trial design were discussed
extensively, but further details still need to be determined
(Box 1). Nevertheless, there was a substantial interest in
the development of and participation in such a trial.
(iv) If I/AHSCT is performed to treat individual patients in clin-
ical practice, comprehensive safety and efﬁcacy data should
be collected, the outcomes submitted to existing registries
such as the Autoimmune Disease Working Party of the
European Society for Blood and Marrow Transplant
(EBMT) (Autoimmune Disease Working Party 2016) and
the Autoimmune Diseases and Cellular Therapies Working
Committee of the Center for International Blood and
Marrow Transplant Research (CIBMTR) (Center for
International Blood and Marrow Research 2016), and the
results published. However, it is strongly encouraged that
efforts be made to enrol such patients into formal clinical
trials of I/AHSCT when available.
Enhanced endogenous cell
therapy including
mesenchymal stem cells
Biological background and rationale
Many stem cell types have potentially beneﬁcial properties
unrelated to trans-differentiation and cell replacement. These
‘non-canonical’ properties, some paracrine, may in some dis-
orders play a greater therapeutic role than conventional cell
replacement (Korbling and Estrov, 2003). In neurological
disease, neural stem cells, MSCs from bone marrow or
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other sources including adipose tissue, and haematopoietic
stem cells have all been shown to have therapeutic potential
that depends on such non-canonical properties (Pluchino
et al., 2005; Uccelli et al., 2008; Rice et al., 2013). MSCs
have attracted the most attention in this regard.
MSCs are present in most (possibly all) tissues (Da Silva
Meirelles et al., 2006; Phinney, 2012). Bone marrow con-
tains various non-haematopoietic stem cells, including
MSCs, and MSCs are themselves a heterogeneous popula-
tion (Phinney, 2012). Within the bone marrow, they func-
tion to help maintain the haematopoietic stem cell
developmental niche (Mendez-Ferrer et al., 2010), but it
is increasingly clear they also play a signiﬁcant systemic
role in repair in many tissues. In some diseased or damaged
tissues, MSC differentiation into cells of the mesodermal
lineage contributes to their putative beneﬁt, for example,
in liver and cardiac disease. Despite early reports of
trans-differentiation into both neurons and oligodendro-
cytes (Woodbury et al., 2000), this phenomenon probably
does not play a signiﬁcant role in potential repair-promot-
ing effects of MSCs in the CNS. Rather, their multiple
paracrine and other mechanisms of action are more rele-
vant (Box 2), offering the prospect of ameliorating a
number of the differing pathological processes contributing
to tissue damage in multiple sclerosis through what might
be termed ‘enhanced endogenous cell therapy’ (Korbling
and Estrov, 2003; Rice and Scolding, 2004).
Some bone marrow cell subpopulations can reside for
decades in the human brain after transplantation (Cogle
et al., 2004), though it is not yet clear which. There is no
such evidence for MSCs speciﬁcally and, in fact, some evi-
dence indicates that MSCs do not persist in tissues (von
Bahr et al., 2012). Thus, potential therapeutic beneﬁt of
MSC transplantation is likely to be self-limited, suggesting
repeated administration will be necessary.
Practical/procedural background
Source and cell production
The question of whether MSCs from different tissue
sources are identical in all properties is not wholly resolved
(Strioga et al., 2012; Li et al., 2015). This uncertainty is
partly a consequence of the continuing absence of any
unique identifying marker of MSCs. They are consequently
deﬁned by a range of properties (Dominici et al., 2006). So,
the argument becomes almost circular: do cells with this
same deﬁning range of properties have identical additional,
non-deﬁning properties? There may be potentially import-
ant differences between MSCs derived from different
sources, e.g. adipose tissue and bone marrow, and these
differences may, in the future, inﬂuence the choice of
tissue source.
The optimal dose of MSCs in any therapeutic use re-
mains unknown, but a common target is 1–2  106 cells/
Box 1 Key issues related to the proposed trial of I/AHSCT in multiple sclerosis
(1) Inadequacy of currently available evidence on which to base general treatment recommendations about I/AHSCT in multiple sclerosis.
Thus, a phase 3 trial is needed.
(2) Characteristics of the optimal/appropriate study population
(a) Age
(b) Disease duration
(c) Disease phenotype
(d) Disability level
(e) Required pre-study disease activity
(f) Prior exposure to DMTs—Which are required? Which are allowed?
(g) Key exclusion criteria relevant to safety
(3) Comparator group—best available therapy versus specific agent(s)
(4) Sample size and study duration to provide sufficient power to demonstrate clinically meaningful differences in efficacy and safety
(5) Primary outcome
(a) Event-free survival using a composite outcome including clinical and imaging outcomes (NEDA or some modification) versus
disability alone
(b) Role of transplant-related or all-cause mortality and how to assess
(6) Treatment failure criteria, allowable/restricted rescue DMT, and how participants who change therapy are accounted for in the analysis
(7) Allowed use of symptomatic therapies
(8) Optimal conditioning regimen intensity
(9) Optimal graft manipulation (e.g. CD34 + cell selection)
(10) Frequency and duration of follow-up for efficacy and safety
NEDA = no evidence of disease activity.
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kg body weight—a number that makes using primary
MSCs near impossible for clinical use. Therefore, protocols
for expanding cells are widely used (Mosna et al., 2010),
though it has become clear that cycles of expansion signiﬁ-
cantly attenuate many reparative and neuroprotective prop-
erties. In addition, the typical yield limits repeat dosing.
New approaches to expansion therefore continue to be
explored (Hoch and Leach, 2014).
Some studies used mixed/unseparated cells (Rice et al.,
2010); others administered puriﬁed and culture-expanded
MSCs (Karussis et al., 2010; Yamout et al., 2010; Bonab
et al., 2012; Connick et al., 2012; Cohen et al., 2017).
Some authors have studied modiﬁed MSCs adapted to ex-
press and secrete particular neurotrophins, though less so in
multiple sclerosis models. Others have pre-differentiated
MSCs—for example, using the classic neural stem cell mito-
genic combination of epidermal growth factor and basic
ﬁbroblast growth factor, combined with ‘neurosphere’
culture techniques, to produce cells with MSC-derived
neural stem cell properties (Harris et al., 2012). Lack of
comparative studies of different cell products and of
in vitro markers that relate to therapeutic efﬁcacy preclude
recommendations on the optimal cell production protocol.
As in all clinical cell therapy endeavours, there is need for
rigorous and stringent quality and safety control in cell pro-
duction with, in the case of artiﬁcially expanded cells, assess-
ment of phenotype and karyotype, mutagenesis testing, and
microbiological analysis (Dominici et al., 2006; Mosna et al.,
2010). This safety aspect represents one signiﬁcant reason for
caution in considering patient requests to purchase treatments
from commercial clinics, particularly in countries where med-
ical facilities are arguably less well regulated.
Route of delivery
Directly injecting cells into speciﬁc lesions would provide
little beneﬁt in the diffuse grey and white matter involvement
Box 2 Properties of MSCs and bone marrow-derived cells of potential therapeutic value in
multiple sclerosis
 Remyelination
Both MSCs and unseparated, non-expanded bone-marrow-derived cells promote myelin repair following intravenous injection (Sasaki et al.,
2001; Akiyama et al., 2002). The mode of action is not clear. Intravenously-delivered bone marrow-derived cells successfully infiltrate the
brain and spinal cord, inflamed or otherwise (Devine et al., 2003; Gordon et al., 2010); and they proliferate and migrate towards cytokines
expressed in multiple sclerosis lesions (Rice and Scolding, 2010). Stimulation of CNS endogenous neural precursors (Munoz et al., 2005; Bai
et al., 2009), and the release of trophic factors for oligodendrocytes might underlie this effect (Pisati et al., 2007).
 Reduced gliotic scar formation (Li et al., 2005)
Gliosis is widely considered to inhibit spontaneous myelin repair.
 Angiogenesis (Bronckaers et al., 2014)
Angiogenesis would also likely enhance tissue repair.
 Suppression of inflammation, immune modulation
Bone marrow-derived cells have pronounced immune-modulating properties (Prockop and Oh, 2012), affecting both innate and adaptive
immune systems. Numerous studies have shown both MSCs and mixed populations of bone marrow-derived cells successfully to
abrogate experimental autoimmune encephalomyelitis through increasingly well understood immunosuppressive actions (Bai et al.,
2009; Morando et al., 2012). Many consider these immune effects sufficiently potent to justify clinical testing in relapsing-remitting
multiple sclerosis [MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS)] (Freedman et al., 2010). However, it should be noted that
animal and human MSC responses can be differentially modulated in both pro- and anti-inflammatory directions by environmental
factors, such as pathogen-associated molecules and cytokines (Darlington et al., 2010; Rozenberg et al., 2016).
 Neuroprotection
MSCs reduce axon loss in various immune-mediated experimental autoimmune encephalomyelitis models (Zhang et al., 2006), but also
in non-immune CNS injury, e.g. stroke models (Chen et al., 2001). Neuroprotective mechanisms include the release of superoxide
dismutase-3 (Kemp et al., 2010) and of various neurotrophins (GDNF, BDNF, HGF) (Bai et al., 2012). MSCs also promote CNS neuritis
outgrowth, and remodelling (Shen et al., 2011).
 Cell fusion
Bone marrow-derived cells fuse with certain differentiated cell types, including neuronal subpopulations, a phenomenon which is
increased in local or systemic inflammation or immune activation, and which likely represents a means of ‘rescuing’ damaged cells
and restoring them to normal function (Johansson et al., 2008; Kemp et al., 2014). Transferring mitochondria from MSC to damaged cells
can also protect tissue (Rice et al., 2010; Prockop, 2012), membrane fusion (likely relating to nanotube formation or exosome transfer)
representing the underlying mechanism common to both cell fusion and mitochondrial ‘donation’. Fusion of infiltrating endogenous bone
marrow-derived cells with Purkinje cells appears to occur spontaneously in multiple sclerosis (Rice et al., 2010; Kemp et al., 2012).
BDNF = brain-derived neurotrophic factor; GDNF = glial derived neurotrophic factor; HGF = hepatocyte growth factor.
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that characterizes multiple sclerosis. Cell therapy delivered
systemically (as with any conventional drug) may have
more rationale—and is safer. Most studies of MSCs have
adopted intravenous injection (Rice et al., 2010; Odinak
et al., 2011; Connick et al., 2012; Li et al., 2014; Llufriu
et al., 2014; Lublin et al., 2014; Cohen et al., 2017).
Following intravenous injection, many cells are trapped
in the lungs, but signiﬁcant numbers still enter the CNS,
become widely distributed, and can remain for decades, as
shown in experimental models and in human subjects
(Cogle et al., 2004). Emerging evidence also suggests
potential immune-modulating effects result from the inter-
action of MSCs and immune cells in the lung (Lee et al.,
2009; Odoardi et al., 2012). Intra-arterial (carotid) deliv-
ery of bone marrow-derived MSCs has been explored in
multiple system atrophy (Lee et al., 2012), but not in
multiple sclerosis to date. Concerns about micro-embol-
ization have limited enthusiasm for this approach.
Intrathecal delivery also has been tested in multiple scler-
osis (Liang et al., 2009; Riordan et al., 2009; Karussis
et al., 2010; Yamout et al., 2010). In the absence of a
head-to-head comparison study, the optimal route of
delivery remains uncertain.
Clinical results to date
Various groups have published small studies exploring
feasibility and safety of MSC transplantation in multiple
sclerosis (summarized in Table 2). These studies involved
differing study populations, cell products, and routes of
administration. The results generally supported the feasibil-
ity and safety of MSC transplantation in multiple sclerosis,
as was expected based on studies in other conditions (Lalu
et al., 2012), including no evidence of ectopic tissue forma-
tion (von Bahr et al., 2012). Transient aseptic meningitis
was common with intrathecal delivery (Karussis et al.,
2010). Also, there have been case reports of acute dissemi-
nated encephalomyelitis after intrathecal MSC injection
(Kishk et al., 2013); a glioproliferative spinal cord
tumour after intrathecal injection of a combination of mes-
enchymal, embryonic, and foetal neural stem cells
(Berkowitz et al., 2016); and severe visual loss in three
patients with age-related macular degeneration after intra-
vitreous injection of adipose tissue-derived stem cells
(Kuriyan et al., 2017). Some uncontrolled studies reported
preliminary evidence of beneﬁt on clinical, neurophysio-
logical, or imaging outcomes (Rice et al., 2010; Connick
et al., 2012; Cohen et al., 2017).
The consensus among workshop participants was that
further clinical trials were warranted. Larger, controlled
phase 2 studies of both unseparated, non-expanded bone
marrow-derived cells (Rice et al., 2015a, b) and puriﬁed,
culture-expanded MSCs [MEsenchymal StEm Cells for
Multiple Sclerosis (MESEMS)] (Freedman et al., 2010) are
underway.
Key questions/issues and
recommendations
Workshop participants identiﬁed several methodological
issues concerning MSC transplantation in multiple sclerosis
(Box 3).
Cell numbers and types
Cell dose currently is entirely empirical; there is little or no
evidence indicating how many cells might be optimal.
Similarly, there is no clear evidence whether multiple infu-
sions would be needed, though this appears intuitively
likely, and exploratory trials are underway (Rice et al.,
2015b). A further issue is the type of cell preparation to
be used. Most studies used mixed mononuclear cell prep-
arations or puriﬁed culture-expanded MSCs; some investi-
gators studied MSC-derived neural progenitors (Harris
et al., 2012). MSCs are much studied experimentally, and
there is an attractive rationale in using a puriﬁed homogen-
ous cell population (Freedman et al., 2010). However, bone
marrow mononuclear preparations include many cell types,
and there is good experimental evidence of beneﬁt of such
mixed preparations in repairing demyelination (Akiyama
et al., 2002) and suppressing inﬂammation, as well as clin-
ical evidence in patients with stroke and other diseases
(Savitz et al., 2011). We do not know which cells among
the bone marrow population are the most valuable thera-
peutically; there is no known beneﬁt from excluding cell
populations. Indeed, some evidence points to the superior-
ity in certain experimental situations of using mixed mono-
nuclear preparations over puriﬁed MSCs. The former
simpler approach requires fewer technical resources and
avoids the potential risks of genetic instability (Miura
et al., 2006), infection (Uhlin et al., 2014), and altered
phenotype that may accompany multiple cell cycling in cul-
ture for expansion. At present, it appears reasonable for
both approaches to be pursued.
It is unclear whether the underlying biology of multiple
sclerosis might affect MSC function. Some studies have
demonstrated similar growth in culture, differentiation po-
tential, surface antigen expression, and immunomodulatory
properties of MSCs isolated from multiple sclerosis subjects
versus non-multiple sclerosis controls (Papadaki et al.,
2005; Mazzanti et al., 2008; Mallam et al., 2010; Kassis
et al., 2013). Other studies reported notable functional dif-
ferences (de Oliveira et al., 2015; Redondo et al., 2016;
Sarkar et al., 2016), suggesting autologous cell transplant-
ation might not be appropriate. Commercial studies using
pooled culture-expanded (heterologous) MSCs in non-mul-
tiple sclerosis conditions have, thus far, had disappointing
efﬁcacy results. Issues of donor variance, immunogenicity,
culture expansion, epigenetic reprogramming, senescence,
and (perhaps particularly) cryopreservation and thawing
(Francois et al., 2012; Chinnadurai et al., 2014, 2016)
may have contributed to these negative results.
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Consensus recommendations
MSC and related cell therapy is an active area of research.
Several phase 2 trials are already underway (Freedman
et al., 2010; Rice et al., 2015a), which should clarify
whether this approach is a potentially efﬁcacious treatment
for multiple sclerosis and in what phase of the disease.
Workshop participants agreed it remains important to
monitor carefully for long-term adverse effects, perhaps
through international registries.
If the concept that underlies MSC therapy proves to be of
beneﬁt in diseases like multiple sclerosis, it may be that
enhanced endogenous cell therapy will ultimately give way
to molecular treatments. If the main beneﬁcial effects of
MSC therapy are paracrine, these might be more conveniently
reproduced by directly using the principal effectors elaborated
by inﬁltrating cells. The problem, however, is that not all the
multiple therapeutic capacities of MSC-related populations
are uniformly activated in all disease situations. Rather, inﬁl-
trating cells probably ‘sense and react’, with speciﬁc pathways
triggered in response to the tissue and form of tissue damage
(Murphy et al., 2013). This process is likely dynamic, with
the proﬁle of administered cells and of those inﬁltrating tis-
sues evolving with the progress of each individual disease or
injury. It may be challenging to reproduce this by adminis-
tering molecules rather than cells.
Pharmacological
manipulation of endogenous
repair mechanisms
Biological background and rationale
The traditional approach to develop remyelination-promoting
pharmacologic therapies begins with basic studies of myelin-
ation and remyelination followed by development of agents
that augment these processes. Such studies have identiﬁed a
sizable number of candidate therapeutics (Kremer et al.,
2016). When the agents are novel, e.g. the anti-LINGO-1
monoclonal antibody opicinumab (Mi et al., 2013), they
then must go through the standard regulatory approval pro-
cess of preclinical studies then phase 1–3 clinical trials (Mi
et al., 2013). However, a sizable number of already existing
medications also may have the ability to promote remyelina-
tion (Kremer et al., 2016); ‘repurposing’ these agents could
expedite testing and regulatory approval. A complementary
molecular approach involves using cultured OPCs or OPC-
like iPSCs as the basis for high-throughput screening of
libraries of already available drugs for their ability to stimu-
late remyelination (Deshmukh et al., 2013; Mei et al., 2014;
Najm et al., 2015). Molecules identiﬁed in the initial screens
were further evaluated by increasingly stringent in vitro and
in vivo testing, identifying the muscarinic antagonist benztro-
pine, the antihistamine clemastine, the imidazole antifungal
miconazole, and the topical steroid clobetasol as potentialT
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candidates for further testing (Deshmukh et al., 2013; Mei
et al., 2014; Najm et al., 2015).
Practical/procedural background
Agents identiﬁed through the approaches described above
are anticipated to have a wide range of mechanisms of
action and pharmacological properties. Therefore, the
design of proof-of-principle clinical trials in multiple scler-
osis will vary according to the agent under study.
Clinical trials to date
A pilot study of clemastine fumarate to promote inherent
remyelination showed improvement on visual evoked po-
tentials in participants with multiple sclerosis-related
chronic optic neuropathy (Green et al., presented at the
2016 Annual Meeting of the American Academy of
Neurology). The RENEW trial of opicinumab in acute
optic neuritis demonstrated beneﬁt on visual evoked poten-
tial latency recovery in the per-protocol analysis but not in
the intention-to-treat analysis or on visual function or op-
tical coherence tomography measures (Cadavid et al.,
2017). The SYNERGY trial of opicinumab in relapsing
multiple sclerosis did not demonstrate beneﬁt on the pri-
mary endpoint, percentage of participants with conﬁrmed
improvement on a composite outcome measure comprising
EDSS, timed 25-foot walk, 9-hole peg test, and paced audi-
tory serial addition test (Cadavid et al., 2016).
Key questions/issues and
recommendations
A number of studies of such agents are underway or planned.
The key question is whether medications identiﬁed through
basic studies of myelination/remyelination or high throughput
screening, in fact, promote remyelination in patients with mul-
tiple sclerosis and how to demonstrate it. Some of the theor-
etical problems applying to the potential use of remyelinating
cells, as outlined below, also apply—for example, the question
of whether degenerated axons can support remyelination.
Oligodendrocyte progenitor
cells and induced pluripotent
cells
Biological background and rationale
Cell-based remyelinating strategies have long been of inter-
est as a potential therapeutic approach in progressive mul-
tiple sclerosis. Glial progenitor cells expressing A2B5 but
not polysialylated neural cell adhesion molecule can be iso-
lated from foetal human brain (Windrem et al., 2004), and
when injected intracerebrally into hypomyelinating shiverer
mice mediate widespread myelination and reversal of the
clinical phenotype (Windrem et al., 2008). These cells can
be further puriﬁed by selecting for expression CD140a and
Box 3 Key issues related to future trials of MSC transplantation in multiple sclerosis
(1) Cell product
(a) Tissue source: bone marrow versus adipose tissue versus other tissues
(b) Mixed/unseparated cells versus purified cultured-expanded cells
(c) Cryopreserved and thawed versus unfrozen
(d) Autologous versus heterologous
(2) Route of delivery: intravenous versus intrathecal versus intra-arterial versus a combination
(3) Dose and dosing
(a) Cell number
(b) Single versus multiple infusions
(4) Trial design
(a) Appropriate study population
(b) Primary trial outcome—should it focus on anti-inflammatory effects or repair?
(c) Comparator
(d) Allowed concomitant multiple sclerosis DMT(s): how might available multiple sclerosis DMTs affect success/viability of MSC
transplantation?
(e) Safety monitoring, short and long term
(i) Infusion-related toxicity
(ii) Acute and late infection
(iii) Ectopic tissue formation
(iv) Cancer
(5) How might underlying multiple sclerosis disease process affect success/viability of MSCs as a treatment approach?
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platelet-derived growth factor alpha receptor, which yields
the more potent myelinogenic fraction (Sim et al., 2011).
Similarly, iPSCs might be used as a source of oligodendro-
cytes, with the potential for autologous cells to be used
(Thiruvalluvan et al., 2016). There are a number of poten-
tial therapeutic targets for such cells (Goldman et al.,
2012), including genetic dysmyelinating disorders, trau-
matic brain and spinal cord injury, and acquired inﬂamma-
tory demyelinating disorders such as multiple sclerosis.
Practical/procedural background
Because OPCs are not expected to be capable of trafﬁcking
from blood or CSF into the CNS parenchyma, it is assumed
that direct injection will be necessary for the cells to gain
access to demyelinated lesions in multiple sclerosis, which
introduces an additional level of technical and safety con-
cerns. It appears that the cells have the capacity to migrate
substantial distances within the CNS (Goldman et al.,
2012), so it may be possible to inject the cells into selected
locations and still obtain widespread repair.
Another issue is that the current principal source of
OPCs is foetal tissue, which provides a limited number of
cells, given the ﬁnite proliferative capacity of OPCs in cul-
ture. Because such cells would be allogeneic, immunosup-
pression of the recipient is required to prevent rejection. It
is reassuring that a previous study demonstrated that cor-
ticosteroids, interferon-beta, and azathioprine did not affect
OPC proliferation, survival, or migratory capacity
(Halfpenny and Scolding, 2003).
For the reasons outlined, generation of OPCs from iPSCs
generated from the recipient is an attractive alternative ap-
proach. However, some studies of human iPSCs have de-
tected frequent genetic modiﬁcations, including aberrant
DNA methylation and mutations in genes implicated in
cancer (Gore et al., 2011; Hussein et al., 2011; Lister
et al., 2011), raising the possibility of aberrant tissue for-
mation or malignant transformation after transplantation.
To design cell lines safe for human use, more research
clearly is required concerning the mechanisms leading to
genetic alterations in iPSCs. As a result, there will be sub-
stantial regulatory hurdles prior to human testing of such
cells. These issues provide much of the impetus for iden-
tifying agents that stimulate remyelination by acting
through intrinsic OPCs rather than relying on administra-
tion of exogenous cells.
Clinical trials to date
A phase 1 trial currently is planned by the New York State
Consortium for Cell Therapy to evaluate the feasibility and
safety of intracerebral injections of escalating doses of
OPCs into multiple locations at a single time point in pa-
tients with secondary progressive multiple sclerosis
(Goodman, 2016). To prevent transplant rejection, partici-
pants will receive tacrolimus and mycophenolate mofetil for
6 months then mycophenolate mofetil alone. Safety studies
will include clinical assessment, laboratory studies, and
brain MRI.
Key questions/issues and
recommendations
The planned phase 1 study of OPC transplantation will
focus on feasibility and safety as a prelude to proof-of-prin-
ciple studies evaluating whether administration of exogen-
ous OPCs augments remyelination in multiple sclerosis.
Workshop participants supported further exploration of
OPC transplantation in multiple sclerosis, but with some
reservations (Box 4). Some studies have demonstrated siz-
able numbers of OPC in some chronically demyelinated
lesions (Chang et al., 2002), suggesting that lack of such
cells is not the cause of inadequate remyelination in mul-
tiple sclerosis. Rather, the lack of factor(s) necessary to
support and sustain remyelination, the presence of inhibi-
tory factor(s) in the multiple sclerosis lesion environment,
and inability of degenerated axons to support remyelina-
tion may be the main obstacles. Thus, administration of
exogenous cells may not address the need. Even if the
proof-of-principle with exogenous OPCs can be demon-
strated with reasonable safety, there are several practical
issues that need to be resolved, e.g. the appropriate cell
dose and patient population most likely to beneﬁt.
Ethical considerations
Cell-based therapies for multiple sclerosis are experimental,
and strict adherence to ethical guidelines for human subject
research (World Medical Association Declaration of Helsinki)
helps preserve patient welfare and the integrity of the research
process (Box 5) (Hyun et al., 2008). Speciﬁc guidelines for
human embryonic stem cell research broadly applicable to
cell-based therapies for multiple sclerosis, including the most
recent revision of international guidelines in 2016
(International Society for Stem Cell Research 2016; National
Research Council and Institute of Medicine of the National
Academies; Daley et al., 2016), stress the ethics of procure-
ment, derivation, banking, distribution, and use of cells and
tissues, including somatic tissues and human totipotent or
pluripotent stem cell lines.
Media attention has resulted in some cases of misrepre-
sentation and exaggeration of therapeutic claims for cell-
based therapies for multiple sclerosis and other diseases. In
the consent process, patients need to be clearly informed
that the cell-based therapy procedure is not ‘standard of
care’. Background information must include what is
known about the procedures they are considering and
what the goals are of the study in which they will partici-
pate. Close attention must be paid to known safety con-
cerns and the potential for unanticipated adverse events.
The existence of many stem cell clinics around the world
has resulted in ‘medical tourism’ by patients who believe
they have exhausted other routes of treatment and are
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willing sometimes to travel great distances to unregulated
clinics for cell-based therapies (Lindvall and Hyun, 2009;
Gunter et al., 2010; New York Times, 2016). Patients are
usually asked to pay for the care directly, without insur-
ance reimbursement. Often such clinics are—for obvious
reasons—based in jurisdictions with less stringent medical
regulatory structures, and so there can often be little if any
assurance of the expertise, quality of care (or even hygiene),
or ethical standards of the provider centre, which is often
unwilling or unable to seek more traditional ﬁnancial sup-
port for their ‘research’. Freestanding stem cell clinics,
which are as yet largely unregulated, have also opened in
Western Europe and the USA, so the issue is becoming
more widespread (Turner and Knoepﬂer, 2016). In fact,
there is a proposed change in the law in the USA, the so-
called REGROW Act, which would remove the require-
ment for formal clinical trials for regulatory approval of
cell-based therapies. Caution against this change has been
urged (Nature Editorial, 2016).
Workshop participants agreed that, at present, all cell-
based therapies lack deﬁnitive evidence for efﬁcacy in mul-
tiple sclerosis and, thus, should be considered experimental
and only pursued in rigorous clinical trials and observa-
tional studies with the expectation that the results will be
published. Clinics offering such therapies should, at min-
imum, conﬁrm that individuals with appropriate qualiﬁca-
tions, training, and experience administer the treatment.
There should be a written treatment plan, including how
complications will be monitored and managed, that can be
reviewed and approved by the treating physician. In the
case of I/AHSCT, workshop participants acknowledged
that there are rare patients with highly aggressive multiple
sclerosis not adequately controlled by available DMTs for
whom this approach can appropriately be considered as
part of clinical practice. In this case, it should be performed
at centres with experience both in the procedure and with
managing multiple sclerosis, and the outcomes submitted to
existing registries and ultimately published.
Workshop participants considered the complex issues of
patient-funded research, in which study participants provide
ﬁnancial support for clinical trials. We acknowledged that this
approach might be a potential option to allow progress in the
ﬁeld given the limited availability of grant funding. However,
a number of concerns were emphasized. Having participants
fund research, particularly pay-to-participate, can accentuate
therapeutic misconception; may compromise the scientiﬁc
merit and integrity of the trial; and should only be undertaken
if the trial is reviewed, approved, and monitored by an inde-
pendent review body, such as an institutional review board or
data safety monitoring committee for the protection of human
subjects in research (Wenner et al., 2015).
Future directions
Cell-based therapies in multiple sclerosis have been pursued
experimentally for at least four decades (Blakemore, 1977),
and the past few years have witnessed considerable pro-
gress. Each of the cell-based approaches discussed above
has begun to enter clinical trials. Much work remains,
however. There is no clear consensus about their relative
roles, especially in comparison with available DMTs, the
speciﬁcs of the procedures, or the most appropriate patient
population and study design to demonstrate short- and
long-term safety and efﬁcacy.
In spite of these uncertainties, there was agreement
among workshop participants that I/AHSCT appears to
have potent efﬁcacy in relapsing-remitting multiple sclerosis
though with signiﬁcant safety concerns. The principal ques-
tion is where I/AHSCT should be placed in the overall
treatment for relapsing-remitting multiple sclerosis. Other
cell-based therapeutic strategies—MSC or OPC/iPSC trans-
plantation, and manipulation of endogenous stem cells—
may be more helpful in patients with progressive forms
of multiple sclerosis where degenerative mechanisms pre-
dominate, but this hypothesis remains to be conﬁrmed.
Thus, all forms of cell-based therapy for multiple sclerosis
should be considered experimental at this time. There may
be rare patients with highly aggressive relapsing-remitting
multiple sclerosis who have failed available therapies for
whom I/AHSCT may be justiﬁed. Other than these patients,
cell-based therapy of multiple sclerosis should be pursued
only in rigorous clinical trials. In all cases, comprehensive
safety and efﬁcacy data should be collected and submitted
to existing registries, with the expectation that the results
will be published.
It seems clear that the most efﬁcient approach to cell-
based therapeutic trials for a relatively uncommon disease
with approved, available DMTs like multiple sclerosis, is
not through the independent effort of many disconnected
clinical centres, but through the development of stable, in-
clusive networks of investigators involved in a spectrum of
cell-based therapies. Such networks can function beyond
the organization of a single multicentre clinical trial
and can establish protocols; undertake studies; and import-
antly set up registries to record transplantation protocols
and outcomes. The Autoimmune Disease Working Party
of the EBMT and the Autoimmune Diseases and Cellular
Therapies Working Committee of the CIBMTR (Center for
International Blood and Marrow Research, 2016) maintain
longstanding registries of patients with autoimmune dis-
orders, including multiple sclerosis, undergoing I/AHSCT.
More recently, networks have been established for MSC
transplantation trials (MESEMS) (Freedman et al., 2010).
Given the experimental status of cell-based therapy, we rec-
ommend all patients undergoing these procedures either in
trials or in clinical practice are recorded in registries. In
addition, important biological questions remain for all
forms of cell-based therapy. Therefore, well designed mech-
anistic studies using validated methods for sample procure-
ment and handling also should be included.
Undertaking clinical trials is a costly enterprise, even
without the creation and maintenance of networks and col-
laborative working groups. It is unlikely that any single
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source can meet all funding needs. Collaborative funding
networks for such efforts have been created, for example,
the International Progressive Multiple Sclerosis Alliance;
the New York State Consortium for Stem Cell Therapy
for Progressive Multiple Sclerosis; government agencies
such as Immune Tolerance Network of the National
Institute of Immunology Allergy and Infectious Disease
and National Institute of Neurological Disorders and
Stroke, the National Institute of Heart Lung and Blood,
the National Cancer Institute, all of the United States
National Institutes of Health; and others. Public-private
funding consortia will likely be needed to raise sufﬁcient
funds to undertake studies and to create and maintain net-
works and registries. While there is documented interest in
such support from private foundations, care needs to be
taken to avoid confusion between the concepts of ‘care’
and ‘research’ in the absence of public support and inde-
pendent oversight. The issues of private stem cell clinics,
which ‘sell’ research that is supported by patients undergo-
ing treatment, are fraught with ethical and practical
concerns.
Given the interest in all forms of cell-based therapies for
multiple sclerosis, and the increasing number of observational
and randomized studies that are being done and proposed,
there will likely be more opportunities than funds available.
Prioritization among opportunities will be important for fun-
ders as well as investigators, and encouraging creation of
research networks will encourage efﬁciencies for both scien-
tiﬁc progress and expenditure of limited funds.
Concluding remarks
(i) Immunoablation followed by autologous haematopoietic
stem cell transplantation appears to have potent and durable
efﬁcacy in relapsing-remitting multiple sclerosis though with
signiﬁcant safety concerns. The principal question is where
this therapeutic approach should be placed in the overall
treatment for relapsing-remitting multiple sclerosis.
(ii) There may be rare patients with highly aggressive relapsing-
remitting multiple sclerosis who have failed available thera-
pies for whom I/AHSCT may be justiﬁed as part of clinical
practice. Other than these patients, cell-based therapy of
multiple sclerosis should be pursued in clinical trials.
(iii) Cell-based therapy—transplantation, mobilization, and
pharmacologic manipulation—may be helpful in patients
with progressive forms of multiple sclerosis where
Box 4 Key issues related to future trials of OPC transplantation in multiple sclerosis
(1) Cell product
(a) Foetal versus derived from embryonic stem cells versus OPC-like iPSC lines derived from the recipient
(i) Issue of genetic modifications in cultured autologous lines
(ii) Potential for ectopic tissue formation
(b) Need for immunosuppression for allogeneic cells
(c) Cell manipulation to stimulate inherent remyelination capacity of exogenous OPCs
(2) Route of delivery
(a) Is direct injection necessary? Can the cells be administered intrathecally?
(b) What is the ability of injected cells to migrate to areas of need within the CNS
(3) Dose and dosing
(a) Cell number
(b) Injection into a single versus multiple locations
(c) Single versus repeated administration
(4) Trial design
(a) Appropriate study population
(b) Allowed concomitant multiple sclerosis DMT(s). How do available multiple sclerosis DMTs affect the viability and function of
transplanted OPCs?
(c) Safety monitoring, short and long term
(i) Adverse effects related to administration e.g. infection, haemorrhage
(ii) Ectopic tissue formation
(iii) Cancer
(iv) Adverse effects related to immunosuppression
(d) What is the effect of immunosuppression to prevent transplant rejection on the viability and/or function of transplanted cells?
(e) How to monitor fate of injected cells
(f) What information on efficacy can be obtained from a phase 1 study focusing on feasibility and safety?
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degenerative mechanisms predominate, but this hypothesis
remains to be conﬁrmed.
(iv) All forms of cell-based therapy for multiple sclerosis should
be considered experimental at this time. When it is pursued,
comprehensive safety and efﬁcacy data should be collected
and submitted to existing registries, with the expectation
that the results will be published. Because important biolo-
gical questions remain for all forms of cell-based therapy,
mechanistic studies should be included.
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(2) Studies must adhere to local guidelines for use of human embryonic and other stem cells related to procurement, cell production,
banking, distribution, etc
(3) Issues related to the proliferation of stem cell clinics and medical tourism
(a) Misconceptions created by media hype
(b) Adequate informed consent
(c) Confusion regarding the distinction between clinical care, innovation, and research
(d) Legitimacy of patient funded research, particularly pay-for-participation
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